Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (41-50 of 272) with videos related to

Pageof 28
Sort By:
Clinical Lung Cancer|July 3, 2017
An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic ApproachBarbara Melosky, Sanjay Popat, David R Gandara
Targeted Oncology|January 29, 2026
Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung CancerDavid John McMahon, Alexius John, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)|December 1, 2011
True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancerJermaine I G Coward, Ravindhi Nathavitharana, Sanjay Popat
European Journal of Cancer (Oxford, England : 1990)|November 21, 2016
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancerTimothy A Yap, Aislinn Macklin-Doherty, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)|April 3, 2007
Malignant pleural mesothelioma: two cases in first degree relativesAnna Wilkins, Sanjay Popat, Sarah Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: End of the Road or the First Chapter?Thanika Ketpueak, Daniel S W Tan, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinibNiamh Coleman, Andrew Wotherspoon, Nadia Yousaf, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2026
"Hiding in Plain Sight: The Neuro-Protective Benefit of Tropomyosin Receptor Kinase Inhibition in Non-Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers": Supporting a Neuroprotective Effect of Lorlatinib Across ALK and ROS1 TargetsDavid König, Thubeena Manickavasagar, Dharmisha Chauhan, et al.
The British Journal of Dermatology|June 7, 2022
Atezolizumab-induced linear IgA bullous dermatosisSilvia Aguilar-Duran, John Mee, Sanjay Popat, et al.
The Lancet. Respiratory Medicine|April 20, 2015
Never smoker with ground glass opacities on CTEric Lim, Andrew G Nicholson, Simon Padley, et al.
Pageof 28

Showing results (41-50 of 272) with videos related to

Sort By:
Pageof 28
Clinical Lung Cancer|July 3, 2017
An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic ApproachBarbara Melosky, Sanjay Popat, David R Gandara
Targeted Oncology|January 29, 2026
Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung CancerDavid John McMahon, Alexius John, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)|December 1, 2011
True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancerJermaine I G Coward, Ravindhi Nathavitharana, Sanjay Popat
European Journal of Cancer (Oxford, England : 1990)|November 21, 2016
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancerTimothy A Yap, Aislinn Macklin-Doherty, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)|April 3, 2007
Malignant pleural mesothelioma: two cases in first degree relativesAnna Wilkins, Sanjay Popat, Sarah Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: End of the Road or the First Chapter?Thanika Ketpueak, Daniel S W Tan, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinibNiamh Coleman, Andrew Wotherspoon, Nadia Yousaf, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2026
"Hiding in Plain Sight: The Neuro-Protective Benefit of Tropomyosin Receptor Kinase Inhibition in Non-Neurotrophic Receptor Tyrosine Kinase-Driven Lung Cancers": Supporting a Neuroprotective Effect of Lorlatinib Across ALK and ROS1 TargetsDavid König, Thubeena Manickavasagar, Dharmisha Chauhan, et al.
The British Journal of Dermatology|June 7, 2022
Atezolizumab-induced linear IgA bullous dermatosisSilvia Aguilar-Duran, John Mee, Sanjay Popat, et al.
The Lancet. Respiratory Medicine|April 20, 2015
Never smoker with ground glass opacities on CTEric Lim, Andrew G Nicholson, Simon Padley, et al.
Pageof 28